E Therapeutics (GB:ETX) has released an update.
e-Therapeutics plc, a pioneer in RNAi medicines discovery, announced the successful passing of all resolutions at their General Meeting, resulting in the delisting of the company’s shares from AIM effective 9 May 2024. A matched bargain facility managed by JP Jenkins will be established to aid share transactions post-delisting. This strategic move aligns with the company’s regulatory progress, specifically the conditional Subscription under the NSIA, which is set to complete simultaneously with the Richard Griffiths Subscription.
For further insights into GB:ETX stock, check out TipRanks’ Stock Analysis page.
